These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18548979)

  • 1. Epoetin-alpha: preserving kidney function via attenuation of polymorphonuclear leukocyte priming.
    Kristal B; Shurtz-Swirski R; Tanhilevski O; Shapiro G; Shkolnik G; Chezar J; Snitkovsky T; Cohen-Mazor M; Sela S
    Isr Med Assoc J; 2008 Apr; 10(4):266-72. PubMed ID: 18548979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease.
    Sela S; Shurtz-Swirski R; Cohen-Mazor M; Mazor R; Chezar J; Shapiro G; Hassan K; Shkolnik G; Geron R; Kristal B
    J Am Soc Nephrol; 2005 Aug; 16(8):2431-8. PubMed ID: 15987755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients.
    Kristal B; Shurtz-Swirski R; Shasha SM; Manaster J; Shapiro G; Furmanov M; Hassan K; Weissman I; Sela S
    Nephron; 1999; 81(4):406-13. PubMed ID: 10095176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients.
    Mazor R; Shurtz-Swirski R; Farah R; Kristal B; Shapiro G; Dorlechter F; Cohen-Mazor M; Meilin E; Tamara S; Sela S
    Atherosclerosis; 2008 Apr; 197(2):937-43. PubMed ID: 17869258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in continuous ambulatory dialysis patients.
    Shurtz-Swirski R; Kristal B; Shasha SM; Shapiro G; Geron R; Sela S
    Nephron; 2002 Aug; 91(4):759-61. PubMed ID: 12138286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Polymorphonuclear leukocyte priming and counts are in correlation with blood pressure parameters].
    Mazor R; Shurtz-Swirski R; Sela S; Shapiro G; Kristal B
    Harefuah; 2006 Dec; 145(12):900-3, 941. PubMed ID: 17220029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress and inflammation due to peripheral polymorphonuclear leukocytes after coronary angiography vs percutaneous coronary intervention.
    Farah R; Shurtz-Swirski R; Bolotin Y; Brezins M
    Minerva Cardioangiol; 2008 Apr; 56(2):189-95. PubMed ID: 18319697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The polymorphonuclear leukocyte--a new target for erythropoietin.
    Sela S; Shurtz-Swirski R; Sharon R; Manaster J; Chezar J; Shkolnik G; Shapiro G; Shasha SM; Merchav S; Kristal B
    Nephron; 2001 Jul; 88(3):205-10. PubMed ID: 11423750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients: effect of statins.
    Farah R; Shurtz-Swirski R; Dorlechter F
    Minerva Cardioangiol; 2010 Apr; 58(2):175-81. PubMed ID: 20440247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
    Trkulja V
    Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The involvement of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation among cigarette smokers.
    Sela S; Shurtz-Swirski R; Awad J; Shapiro G; Nasser L; Shasha SM; Kristal B
    Isr Med Assoc J; 2002 Nov; 4(11):1015-9. PubMed ID: 12489494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of statins on oxidative stress and primed polymorphonuclear leukocytes in hyperlipidemic patients.
    Farah R; Jubran F; Khamisy-Farah R
    Biotech Histochem; 2012 Nov; 87(8):519-25. PubMed ID: 22989353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients.
    Farah R; Shurtz-Swirski R
    Minerva Cardioangiol; 2008 Oct; 56(5):467-76. PubMed ID: 18813182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietic agents and the elderly.
    Agarwal N; Prchal JT
    Semin Hematol; 2008 Oct; 45(4):267-75. PubMed ID: 18809098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance.
    Emans ME; van der Putten K; van Rooijen KL; Kraaijenhagen RJ; Swinkels D; van Solinge WW; Cramer MJ; Doevendans PA; Braam B; Gaillard CA
    J Card Fail; 2011 Aug; 17(8):626-33. PubMed ID: 21807323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment.
    Siems W; Carluccio F; Radenkovic S; Grune T; Hampl H
    Kidney Blood Press Res; 2005; 28(5-6):295-301. PubMed ID: 16534224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
    Lefebvre P; Duh MS; Mody SH; Bookhart B; Piech CT
    Dis Manag; 2007 Feb; 10(1):37-45. PubMed ID: 17309363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.